Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...
Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a chilling effect on vaccine makers as ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...
The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results